CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
N-Acetylcysteinedrug
Likely dose
N-Acetylcysteine 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00542750
NCT00542750Phase 2Completed
CompareCT.gov

An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents

Medical University of South Carolina·interventional·Posted Oct 11, 2007·Updated May 23, 2018

In Brief

A Phase 2 clinical trial evaluating N-Acetylcysteine for Cannabis Dependence. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this pilot study is to determine the feasibility of conducting a trial of N-Acetylcysteine in cannabis dependent adolescents.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), American Academy of Child Adolescent Psychiatry.

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 11, 2007
Enrollment StartJan 1, 2008
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.7 years ago

Interventions

N-Acetylcysteinedrug

N-Acetylcysteine 1200 mg twice daily for four weeks